Navigation Links
Hepatitis C Virus Market Will Expand Dramatically From $2 Billion in 2008 to Nearly $7.7 Billion in 2013
Date:6/22/2009

Roche and Schering-Plough Will Continue to be Prominent Players in the Market, According to a New Report from Decision Resources

WALTHAM, Mass., June 22 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the hepatitis C virus drug market will expand dramatically from $2 billion in 2008 to nearly $7.7 billion in 2013 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. However, market growth thereafter will decrease to $3.4 billion in 2018 owing to a decline in the prevalence of the disease and the high efficacy of new treatment regimens.

The new Pharmacor report entitled Hepatitis C Virus finds that, through 2013, robust market growth will be driven by the launches of novel hepatitis C virus-specific agents and an increase in the size of the drug-treated population. Roche and Schering-Plough will continue to be prominent players and a number of other companies -- including Johnson & Johnson and Pfizer -- will also carve out a share in the market.

The report also finds that the competitive hepatitis C virus pipeline is characterized by its significant commercial potential which is well-recognized by drug developers. Several agents in late-stage development -- most notably protease inhibitors such as Vertex/Johnson & Johnson/Mitsubishi Tanabe's telaprevir and Schering-Plough's boceprevir as well as polymerase inhibitors such as Roche/Pharmasset's R-7128 and Pfizer's filibuvir -- will drive market growth.

"The standard of care will change significantly with the introduction of new classes of hepatitis C virus-specific antiviral agents, such as protease inhibitors and polymerase inhibitors," said Decision Resources Analyst Alexandra Makarova, M.D., Ph.D. "Compounds from these new classes will initially be added to the backbone of currently used agents, forming triple or quadruple treatment regimens that are expected to be more efficacious than the current standard of care."

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                               Decision Resources, Inc.
    Christopher Comfort                              Elizabeth Marshall
    781-296-2597                                     781-296-2563
    ccomfort@dresources.com                          emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Good news for some hard-to-treat hepatitis C patients
2. Aethlon Medical Releases Shareholder Letter to Discuss the Treatment of Hepatitis-C Virus (HCV)
3. Pharmasset Initiates Phase 1b Multiple Ascending Dose Clinical Trial of PSI-7851 in Chronic Hepatitis C Patients
4. NEJM study points to new era in hepatitis C treatment
5. Resource for Those Living with Hepatitis C Announces Website Redesign
6. AUDIO from Medialink, Bayer Healthcare and Onyx Pharmaceuticals: Facts About Hepatitis
7. New treatment option for patients with chronic hepatitis C
8. National Viral Hepatitis Roundtable Observes World Hepatitis Day and Calls for Increased Federal Action
9. National Viral Hepatitis Roundtable Observes World Hepatitis Day and Calls for Increased Federal Action
10. World Health Assembly Forced to Postpone Decision on Viral Hepatitis
11. ImQuest BioSciences and Arisyn Therapeutics Introduce Novel New HCV Therapeutic Agent at Hepatitis Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... (PRWEB) , ... December 05, 2016 , ... ... announced it has been featured in SuperbCrew magazine, a leading online tech news ... world. This interview, now featured on SuperbCrew.com, explores the state of enterprise mobility ...
(Date:12/5/2016)... ... December 05, 2016 , ... Researchers at Johns Hopkins All Children’s ... of young athletes. Over the course of three years, researchers will study concussions and ... The mouth guards, equipped with special sensors, will track the location and force of ...
(Date:12/5/2016)... ... December 05, 2016 , ... “Epilepsy Awareness,” which can be ... sparks a conversation about epilepsy, bearing down on the social stigma and lack ... diagnosed with epilepsy within their lifetime. With such a large percentage of people ...
(Date:12/5/2016)... ... December 05, 2016 , ... Physicians Education Resource®, ... International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma, on February ... are honored to have Amy E. Herman present at this year’s conference, her ...
(Date:12/5/2016)... (PRWEB) , ... December 05, 2016 , ... ... gender, and geographic lines. The goal of Castlewood Treatment Centers has always been ... accessible to as many people as possible. In that spirit, Castlewood has ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... Spain Glaucoma Surgery Devices Market Outlook to ... Surgery Devices Market Outlook to 2022", provides key market ... report provides value, in millions of US dollars, volume ... - Canaloplasty Micro Catheters and Glaucoma Drainage Devices. ... data for each of these market segements, and global ...
(Date:12/5/2016)... N.J. , Dec. 5, 2016  Cornerstone ... company, today presented data from two Phase I ... sessions at the 58th annual meeting of the ... San Diego, California . The two datasets ... with acute myeloid leukemia (AML) and T-cell non-Hodgkin,s ...
(Date:12/5/2016)... 5, 2016  Pennsylvania Physician General Dr. Rachel ... Gary Tennis today filled prescriptions for naloxone, ... in York to demonstrate how ... Levine as a prescription to acquire naloxone at any ... to remember that any Pennsylvanian can walk up to ...
Breaking Medicine Technology: